Oncology

Oncology: Strategic Modeling and Simulation Services

Certara has extensive experience supporting oncology drug development. In addition, we have applied a range of modeling techniques to address critical decisions from pre-clinical to late stage clinical for antibodies, proteins and small molecules, such as C-QT modeling, metadata analysis, preclinical to Phase 2 PK and TK analysis, and PBPK modeling and simulation.

Disease areas:

  • Breast cancer
  • Glioblastoma
  • Melanoma
  • Non-Hodgkin’s lymphoma
  • Non-small cell lung cancer
  • Pancreatic cancer
  • Renal cell carcinoma
  • Acute myeloid leukemia
  • Multiple myeloma
  • Urinary bladder cancer
  • Ovarian cancer
  • Prostate cancer
  • Thyroid cancer

Clinical Trial Outcome Databases:

We have recently developed a paclitaxel mono-therapy database, which includes clinical PK and toxicity information of paclitaxel and efficacy outcomes on paclitaxel in the treatment of advanced or metastatic breast cancer.

Model-informed drug development is helping bring safer, more effective medications to cancer patients. Certara Consulting Services can help sponsors optimize dosing, inform drug labels, achieve regulatory compliance, and in some cases, waive clinical trials.

Learn More
LinkedIn